Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2009

View Archived Issues

T-3.5 combines antimalarial activity with quinolone sensitization

Halozyme initiates phase II insulin plus rHuPH20 trial in type 2 diabetes

Antimelanoma activity with plitidepsin meaningful but limited in phase II study

Antitumor synergy seen with thiarabine-clofarabine combination

FDA approves Onsolis for breakthrough cancer pain

Faes licenses bilastine to Hikma for the Middle East and North Africa

Zogenix obtains U.S. approval for Sumavel DosePro sumatriptan delivery system

Evolva completes phase I single ascending-dose EV-077-3201-2TBS trial

Alnylam extends RNAi therapeutics collaboration with Novartis

FDA evaluates ongoing safety review for Xolair

Shionogi reports results from phase III peramivir studies in seasonal influenza patients

Medicago's avian flu pandemic vaccine achieves 100% protection in animal study

Plethora enters evaluation and option agreement for PSD-503

AstraZeneca signs Australian collaboration to improve early detection of AD

Effects of rosiglitazone XR in Alzheimer's disease probed in phase III study

Natural antidiabetic agent NIC5-15 safe and well tolerated in Alzheimer's disease patients

Pfizer receives European Commission approval for pending acquisition of Wyeth

Phase III Xeloda-oxaliplatin combination data reported in colon cancer

DHA supplements evaluated in cognitive function; clinical data disclosed at ICAD

Siena Biotech describes Hedgehog signaling antagonists

CalciMedica patents CRAC ion channel inhibitors

Telomerase activity inhibitors described by the University of London as antiproliferative agents

Acquisition of Monogram by LabCorp clears antitrust review

Castle Biosciences launches DecisionDx-GBM biomarker test for brain cancer

Biopure files for bankruptcy in the U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...